Efficacy and safety of polyethylene glycol loxenatide as add‐on to metformin in patients with type 2 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3b trial

Fei Gao,Xiaofeng Lv,Zhaohui Mo,Jianhua Ma,Qiu Zhang,Gangyi Yang,Weijuan Liu,Quanmin Li,Jian Zhou,Yuqian Bao,Weiping Jia

DOI: https://doi.org/10.1111/dom.14163

2020-09-06

Diabetes, Obesity and Metabolism

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Aims</h3><p>To assess the efficacy and safety of polyethylene glycol loxenatide (PEX168), a new glucagon‐like peptide receptor agonist, as an add‐on to metformin therapy in Chinese patients with type 2 diabetes mellitus (T2DM).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Materials and methods</h3><p>This was a multicenter, randomized, double‐blind, placebo‐controlled phase 3b trial. After metformin monotherapy (≥1500 mg/day) for ≥8 weeks, patients with uncontrolled T2DM [glycated hemoglobin (HbA1c) 7.0%–10.5%] from 44 sites were randomized (1:1:1) to metformin + placebo, metformin + PEX168 100 μg, and metformin + PEX168 200 μg. The core treatment period lasted for 24 weeks, followed by a 28‐week extension period. The primary endpoint was the change in HbA1c levels at week 24. The main secondary endpoint was the proportion of patients with HbA1c &lt;7.0% at week 24.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The least‐square mean (standard error) change in HbA1c levels was significantly greater (P &lt; 0.001 for superiority) in PEX168 groups [−1.16% (0.08%) and − 1.14% (0.08%) with 100 μg and 200 μg, respectively] than in the placebo group [0.35% (0.08%)]. The proportion of patients with HbA1c &lt;7.0% at week 24 was significantly higher in the PEX168 100 μg (37.4%) and PEX168 200 μg (40.6%) groups than in the placebo group (16.8%, both P &lt; 0.001). The gastrointestinal reactions were mild; the risks of hypoglycemia and weight gain did not increase. Anti‐PEX168 antibodies were noted in less than 2% of patients. No treatment‐emergent SAEs occurred.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>The subcutaneous injection of PEX168 once a week can effectively, continuously, and safely improve HbA1c levels in patients with T2DM when combined with metformin.</p><p>This article is protected by copyright. All rights reserved.</p></section>